UK’s NHS Facing Major Leadership Shake-Up
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
Address: St John’s Innovation Centre Cowley Road Cambridge CB4 0WS ,United Kingdom
Tel: + 44 (0) 1223 421411
Web: http://tiger.directrouter.co.uk/cgi-sys/defaultwebpage.cgi
Altacor is an Ophthalmic Specialty Pharmaceutical Company specialising in marketing and development of differentiated products which have been designed for the needs of both ophthalmologists and patients.
From its headquarters in Cambridge UK, Altacor is using its drug development skills and in depth market knowledge to build a portfolio of high quality, differentiated prescription medicines that set new standards in the sector. The company has a sales infrastructure which is active in the secondary care sector and in accessing primary care and promoting the prescription products Clinitas and Clinitas Gel. Altacor is also working in the pharmacy and optical channels through which its OTC products – the Clinitas range for all dry eye conditions, are being promoted.
Altacor’s pipeline consists of development products for Ocular Surface Disease, Ocular Infection and Glaucoma. The company’s products are differentiated by formulation or reprofiling, patented active or delivery systems and presented in multidose or preservative-free single use containers.
Altacor has strong skills in drug formulation, reprofiling and development through its extensive network and understanding of the European regulatory environment which results in a uniquely focused company.
Altacor has three areas of therapeutic interest
1. Ocular Surface Disease including Dry Eye syndrome
2. Ocular Infection
3. Glaucoma
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
Just one year after the UK government published its Life Science Vision, outlining the ambitions of the government and the life science sector for the next 10 years, the Association…
After a tumultuous year, AstraZeneca is creating a standalone vaccine unit and will begin to charge for its COVID-19 vaccine shot, having previously provided it at cost. PharmaBoardroom looks back…
The latest news from UK pharma, including AstraZeneca’s decision to create a dedicated business unit for its COVID-19 vaccines, GSK’s raised profits forecast, and CDMO Almac’s move to create over…
Cyril Titeux, senior VP mid-sized markets EMEA & strategic leader at Janssen, argues that the current focus of many health systems on efficiency, streamlining, and reducing spending is leaving them…
British pharmaceuticals giant, GSK, one of the UK’s largest companies by market capitalization, is once again finding itself under the spotlight as analysts and shareholders alike continue to query the…
Kathy Pritchard-Jones, Professor of Paediatric Oncology at University College London (UCL) and President of the International Society of Paediatric Oncology (SIOP) discusses the latest advancements in childhood cancer treatment, the…
Zack Pemberton-Whiteley, CEO of UK-based blood cancer charity Leukaemia Care, discusses the importance of patient and patient organizations’ involvement in the decision-making process for therapy appraisals, the use of HTA,…
Stuart Evans, partner at law firm BLM and specialist in commercial disputes and litigation examines the origins and fallout of the EU/AstraZeneca vaccine dispute and why the twin forces of…
The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma giant; CDMO Sterling’s latest acquisition; and calls for a national registry to…
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical company successfully listed on NASDAQ, raising over USD 30 million. Founded…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left…
See our Cookie Privacy Policy Here
